Clearing the airways in cystic fibrosisAugust 29, 2008Research in the FASEB Journal shows that engineered proteins can 'bypass' the genetic defect in cystic fibrosis By manipulating the machinery used by our cells for quality control, researchers from the University of Pittsburgh have found a way to restore the function of cystic fibrosis (CF) airway cells. This could significantly reduce the sticky mucus that plugs the lungs of CF patients, which leads to antibiotic-resistant infections and untimely death. The study, appearing in the September 2008 print issue of The FASEB Journal (http://www.fasebj.org), is significant because it shows a new way to manipulate the cellular quality controls of all sorts of proteins which play a role in conditions ranging from aging to cancer. "Our hope is that this work will provide new approaches for recovering function from the protein whose inability to fold and function properly compromises the quality of life and life expectancies of people with CF," said Raymond Frizzell, senior author on the study. The researchers say, however, that it is too early to tell exactly what other conditions this technique will affect. Most people do not realize that when our bodies produce proteins, they sometimes make mistakes. Similar to what happens on assembly lines, these mistakes are rejected and prevented from being used. In most people with CF, however, defective (i.e., mutant) CFTR proteins made by airway epithelial cells could actually be beneficial if they were allowed to reach their final destination at cell surfaces. To help these mutant proteins (the {DELTA}F508 CF gene mutation) reach cell surfaces, researchers developed a "decoy," made up of only a portion of the complete mutant protein, which is rejected instead. In airway epithelial cells taken from CF patients, the "distracted" airway cells allowed the complete {DELTA}F508 CFTR protein to evade the quality control mechanisms that would have normally destroyed it. "Since this pivotal discovery of the CF gene nearly 20 years ago, researchers have made more progress toward a cure than they had in thousands of years before," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. "People with cystic fibrosis now live longer than once ever thought possible, and basic science breakthroughs like this one keep the trend ever upward." According the U.S. Cystic Fibrosis Foundation, cystic fibrosis affects about 70,000 people worldwide. It is caused by a defective gene and its protein product, which causes the body to produce very thick and sticky mucus. This mucus clogs the lungs and leads to life-threatening lung infections. It also blocks enzymes from the pancreas that needed to break down and absorb food. Sixty years ago, few children with cystic fibrosis lived to attend elementary school. Today, the projected median survival age is 37. Federation of American Societies for Experimental Biology |
|||||||||||||||||||||
| Related Cystic Fibrosis Current Events and Cystic Fibrosis News Articles Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Protein critical for insulin secretion may be contributor to diabetes A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes. New clinical guidelines for exacerbations in cystic fibrosis The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices. Nanoparticle treatment for burns curbs infection, reduces inflammation Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies. Research Matters at the Arizona Health Sciences Center (AHSC): UA Researchers Seek Safer Cystic Fibrosis Test Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers. Species diversity helps ASU researchers refine analyses of human gene mutations In the new era of personalized medicine, physicians hope to provide earlier diagnoses and improve therapy by evaluating patients' genetic blueprints. But, as a new bioinformatics study emphasizes, the first step must be to correctly decipher the deluge of information locked in our DNA and determine its impact on human health. New developments in reproductive medicine Three out of ten women who undergo polar body diagnosis go on to have a child. Faster, cheaper way to find disease genes in human genome passes initial test University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. Mutation responsible for cystic fibrosis also involved in muscle atrophy Patients with cystic fibrosis (CF) usually experience significant muscle loss, a symptom traditionally considered to be a secondary complication of the devastating genetic disease. More Cystic Fibrosis Current Events and Cystic Fibrosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||